Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFITOPE PD01A Second Boost in Parkinson's Disease
NCT02618941Phase 1Completed
- Sponsor
- AFFiRiS
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of AFFITOPE PD03A in Parkinson's disease (PD) (2 arms), sponsored by AFFiRiS. Primary endpoints: Occurrence of any Serious Adverse Events (SAE) related to study drug at 12 months, Number of patients who withdraw due to Adverse Events (AEs) at 12 months and 1 more. Started Feb 2016; status: completed.
02
Drugs
AFFITOPE PD03A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02618941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618941.